Session 6: Insights from Health Care Systems on Bispecifics: Patient Treatment, Monitoring and Transition of Care

home / training-academy / insights-from-healthcare-systems-and-bispecifics-patient-treatment-monitoring-and-transition-of

Binod Dhakal, MD, MS, and a panel of experts in multiple myeloma provide a look at an upcoming Cancer Network Training Academy program discussing how to incorporate bispecific antibodies in the treatment of multiple myeloma, and how healthcare systems implement step-up dosing, treatment doses and transition of care. The panel also offers insights into the recommended strategies for monitoring patients receiving treatment with bispecifics.

Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

EP. 1: Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
May 31st 2023

Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.

Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment

EP. 2: Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
May 31st 2023

Dr Cindy Varga discusses recent data on the FDA-approved agent teclistamab, a bispecific antibody for patients with relapsed/refractory multiple myeloma.

MonumenTAL-1: Evaluating the Anti- GPRC5D-Targetings Bispecific in R/R MM

EP. 3: MonumenTAL-1: Evaluating the Anti- GPRC5D-Targetings Bispecific in R/R MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
June 7th 2023

Dr Jeremy Larsen reviews data from the MonumenTAL-1 study investigating the CD3- and GPRC5D-targeting bispecific antibody talquetamab in relapsed/refractory multiple myeloma.

FCRH5-Targeting and Other Emerging Bispecifics in R/R MM

EP. 4: FCRH5-Targeting and Other Emerging Bispecifics in R/R MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
June 7th 2023

Jeremy Larsen, MD, discusses data from a phase 1/2 study of cevostamab and other emerging bispecifics being evaluated in patients with relapsed/refractory multiple myeloma.

Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US

EP. 5: Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
June 14th 2023

Expert hematologist-oncologists discuss how they incorporate teclistamab in their clinical practice as well as variations in access to bispecifics and CAR T-cell therapy.

Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives

EP. 6: Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
June 14th 2023

The panel discusses the approach to step-up and treatment dosing for bispecifics in their respective health care systems.

Best Practices for Transition of Care in Patients with MM on Teclistamab

EP. 7: Best Practices for Transition of Care in Patients with MM on Teclistamab

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
June 21st 2023

Expert panelists in multiple myeloma share their experiences with implementing bispecifics and transition of care in the community setting for patients with R/R MM.

Managing Infections and Other Toxicities Associated with Bispecifics in MM

EP. 8: Managing Infections and Other Toxicities Associated with Bispecifics in MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
June 21st 2023

Jeremy Larsen, MD, discusses the management of infections, neurotoxicity, and other side effects associated with bispecifics in patients with R/R MM, including the need for prophylactic antimicrobials and monitoring of immunoglobulin levels.

Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment

EP. 9: Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
June 28th 2023

Cindy Varga, MD, details her experience with sequencing BCMA-targeting agents for patients with relapsed/refractory multiple myeloma.

Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment

EP. 10: Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
June 28th 2023

Experts explain the strategies for optimal selection between different BCMA-targeting and non-BCMA-targeting bispecifics for the treatment of relapsed/refractory multiple myeloma.

Future Perspectives on the Role of Bispecifics in MM

EP. 11: Future Perspectives on the Role of Bispecifics in MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
July 5th 2023

Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.

Key Takeaways from Health Care Systems on the Role of Bispecifics in MM

EP. 12: Key Takeaways from Health Care Systems on the Role of Bispecifics in MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
July 5th 2023

The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.

Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma

EP. 13: Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma

ONCOLOGY Staff
September 15th 2023

CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.

Treatment Recommendations for Relapsed Multiple Myeloma

EP. 14: Treatment Recommendations for Relapsed Multiple Myeloma

ONCOLOGY Staff
November 16th 2023

Experts in the multiple myeloma space met to discuss the treatment and monitoring after bispecific antibodies.